利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.026 秒)

    Method for preparing thin regenerated cellulose membranes of high flux and selectivity for organic liquids separations
    1.
    发明授权
    Method for preparing thin regenerated cellulose membranes of high flux and selectivity for organic liquids separations 失效
    制备高通量和有机液体分离选择性的薄再生纤维素膜的方法

    公开(公告)号：US4496456A

    公开(公告)日：1985-01-29

    申请号：US500966

    申请日：1983-06-03

    申请人： Mahmoud M. Hafez ,  Henry W. Pauls

    发明人： Mahmoud M. Hafez ,  Henry W. Pauls

    IPC分类号： B01D67/00 ,  B01D71/10 ,  C10G73/08 ,  C10G73/12 ,  B01D13/00

    CPC分类号： B01D67/0095 ,  B01D67/0011 ,  B01D71/10

    摘要： A method is described for the production of regenerated cellulose membranes which method comprises the steps of:(a) dissolving a cellulose material to form a solution;(b) casting the cellulose solution into a film;(c) coagulating the cellulose solution film using an alkali alcoholic solution;(d) washing the coagulated cellulose film in an alcohol;(e) regenerating the cellulose film using acidic alcohol solution;(f) washing the regenerated cellulose membrane using an alcohol.The regenerated cellulose thus formed may be dried, if desired, preferably without a softener.The regenerated cellulose thus produced, when prepared in the form of a film or membrane, possesses higher flux and superior selectivity for organic liquid separation than regenerated cellulose membranes prepared employing aqueous solutions in steps b through e above and is most advantageously employed for the recovery of polar dewaxing solvents (e.g. ketones and mixed ketone/aromatic solvents) from dewaxed oil.

    摘要翻译： 描述了用于生产再生纤维素膜的方法，该方法包括以下步骤：（a）将纤维素材料溶解以形成溶液; （b）将纤维素溶液浇铸成膜; （c）使用碱醇溶液使纤维素溶液膜凝结; （d）在醇中洗涤凝固的纤维素膜; （e）使用酸性醇溶液再生纤维素膜; （f）使用酒精洗涤再生纤维素膜。 如果需要，如此形成的再生纤维素可以被干燥，优选没有软化剂。 因此制备的再生纤维素当以膜或膜的形式制备时，与使用上述步骤b至e中的水溶液制备的再生纤维素膜相比，具有更高的通量和对有机液体分离的优异选择性，并且最有利地用于回收 来自脱蜡油的极性脱蜡溶剂（例如酮和混合酮/芳族溶剂）。

    Phosphonate derivatives of lipophilic amines
    2.
    发明授权
    Phosphonate derivatives of lipophilic amines 失效
    亲脂胺的膦酸酯衍生物

    公开(公告)号：US5441946A

    公开(公告)日：1995-08-15

    申请号：US227803

    申请日：1994-04-14

    申请人： Henry W. Pauls ,  Yong-Mi Choi ,  Dilip V. Amin

    发明人： Henry W. Pauls ,  Yong-Mi Choi ,  Dilip V. Amin

    IPC分类号： C07F9/38 ,  C07F9/40 ,  C07F9/653 ,  C07F9/6558 ,  A61K31/66 ,  C07F9/44

    CPC分类号： C07F9/65583 ,  C07F9/3808 ,  C07F9/3873 ,  C07F9/4006 ,  C07F9/404 ,  C07F9/405 ,  C07F9/65324

    摘要： This invention relates to a class of novel phosphonate derivatives of lipophilic amines which exhibit squalene synthase inhibition properties. More specifically the compounds are bis aryl cycloalkylamino and azacycloalkyl phosphonates. Compounds of this invention reduce levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention.

    摘要翻译： 本发明涉及一类表现出角鲨烯合酶抑制性质的亲脂胺的新型膦酸酯衍生物。 更具体地，化合物是双芳基环烷基氨基和氮杂环烷基膦酸酯。 本发明化合物降低体内血清胆固醇水平，而不显着降低甲羟戊酸代谢物合成。 本发明还涉及使用本发明化合物降低血清胆固醇水平的药物组合物和治疗方法。

    Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
    7.
    发明授权
    Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties 失效
    具有抗高血压，心脏保护作用，抗缺血性和抗脂解性的化合物

    公开(公告)号：US06376472B1

    公开(公告)日：2002-04-23

    申请号：US09174191

    申请日：1998-10-16

    申请人： Michael R. Myers ,  Martin P. Maguire ,  Alfred P. Spada ,  William R. Ewing ,  Henry W. Pauls ,  Yong Mi Choi-Sledeski

    发明人： Michael R. Myers ,  Martin P. Maguire ,  Alfred P. Spada ,  William R. Ewing ,  Henry W. Pauls ,  Yong Mi Choi-Sledeski

    IPC分类号： C07D47334

    CPC分类号： C07H19/16 ,  C07D401/04 ,  C07D471/04 ,  C07D473/34

    摘要： A compound of the formula wherein K is N; Q is CH2 or O; R6 is hydrogen, alkyl, allyl, 2-methylallyl, 2-butenyl, or cycloalkyl where the nitrogen of the ring of X is substituted by Y; E is O or S; Y is hydrogen, alkyl, aralkyl, substituted aralkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, or substituted heterocyclylalkyl; and n and p are independently 0, 1, 2, or 3, provided that n+p is at least 1; T is hydrogen, alkyl, alkylcarbonyl, alkylthiocarbonyl, halo, carboxyl, A and B are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR′; or a pharmaceutically acceptable salt thereof, a pharmaceutic-ally acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

    摘要翻译： 化合物K为N; Q是CH 2或O; R6是氢，烷基，烯丙基，2-甲基烯丙基，2-丁烯基或环烷基，X的环的氮被Y取代; E为O或S; Y是氢，烷基，芳烷基，取代的芳烷基，芳基，取代的芳基，杂环基，取代的杂环基，杂环基烷基或取代的杂环基烷基; n和p独立地为0,1,2或3，条件是n + p为至少1; T为氢，烷基，烷基羰基，烷硫基羰基，卤素，羧基，A和B独立地为氢，烷基，羟基烷基， 烷氧基烷基或OR';或其药学上可接受的盐，其药学上可接受的前药，其N-氧化物，其水合物或其溶剂化物。